PacBio is refining the CRISPR/Cas9 capture technique with several early- access sites and plans to launch it more broadly in 2018.
The nanopore ZMW can enable lower starting amounts of DNA for PacBio sequencing, and may eventually enable direct RNA sequencing.
The Index gained 4 percent, outperforming the Dow and the Nasdaq, but underperformed the Nasdaq Biotechnology Index, which rose 5 percent.
PacBio has released new software, which has increased read lengths and throughput, and aims to launch a new sample prep protocol and chemistry this year.
Although PacBio's product and services revenues were up 17 percent, total revenues declined 3 percent due to a lack of contractual revenue in the quarter.
The firms plan to focus on sample processing methods, workflow automation, algorithms, and database construction.
The firm is aiming to sell 15.4 million shares of common stock at $3.10 per share, and plans to use the proceeds for working capital and capital expenditures.
The GenomeWeb Index rose nearly 3 percent in May, vastly outperforming the Dow and Nasdaq Biotechnology Index.
The GenomeWeb Index rose nearly 6 percent in April, vastly outperforming the Dow, Nasdaq, and Nasdaq Biotechnology Index.
Pacific Biosciences reported total Q1 2017 revenues of $24.9 million, just beating analysts' average estimate of $24.6 million.
At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.
The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.
Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.
In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.